Investors

News Releases

News Releases

REGENXBIO to Present at Upcoming Investor Conferences

September 6, 2018 at 4:05 PM EDT

ROCKVILLE, Md., Sept. 6, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the following September investor conferences:

Morgan Stanley 16th Annual Global Healthcare Conference
Date:Wednesday, September 12, 2018Thursday, September 13, 2018
Location: Grand Hyatt Hotel, New York, NY
Fireside Chat:Thursday, September 13, 2018 at 11:10 a.m. ET

Jefferies Gene Therapy Summit
Date:Thursday, September 27, 2018
Location:Jefferies Conference Center, New York, NY
Presentation: Thursday, September 27, 2018 at 1:30 p.m. ET

A live webcast of each presentation can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available on the same website for approximately 30 days following each presentation. In addition, REGENXBIO senior management will be holding one-on-one meetings at each of the conferences.

About REGENXBIO

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

CONTACT:

Investors
Natalie Wildenradt, 646-681-8192
natalie@argotpartners.com

Media
Adam Pawluk, 202-591-4063
apawluk@jpa.com

(PRNewsfoto/REGENXBIO Inc.)

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-present-at-upcoming-investor-conferences-300708393.html

SOURCE REGENXBIO Inc.